JCOIN’s National Survey of Substance Use Services in Jails

Describing U.S. Jails and Their Screening, Treatment, Recovery, and Re-entry Practices

Suggested citation:
Contents

01 Survey overview
02 Phase I Sample
03 Availability of Substance Use Disorder (SUD) treatment
04 Types of Medication Assisted Treatment (MAT)
### JCOIN NATIONAL JAIL SURVEY (2022-2023) : OVERVIEW

<table>
<thead>
<tr>
<th>National Survey (&quot;Phase 1&quot;)</th>
<th>Targeted Survey at Jails Providing MAT (&quot;Phase 2&quot;)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dates in field</strong></td>
<td>June 2022 – April 2023</td>
</tr>
<tr>
<td></td>
<td>February 2023– June 2023</td>
</tr>
<tr>
<td><strong>Purpose</strong></td>
<td>Broadly capture screening &amp; treatment in jails across U.S.</td>
</tr>
<tr>
<td></td>
<td>Understand more deeply how OUD is treated in jails</td>
</tr>
<tr>
<td><strong>Instrument</strong></td>
<td>20-minute survey</td>
</tr>
<tr>
<td></td>
<td>45-60-minute in-depth survey</td>
</tr>
<tr>
<td><strong>Administration</strong></td>
<td>Web, mail (i.e., paper), phone</td>
</tr>
<tr>
<td></td>
<td>Web, mail (i.e., paper), phone</td>
</tr>
<tr>
<td><strong>Target Number of Completes</strong></td>
<td>945</td>
</tr>
<tr>
<td></td>
<td>284</td>
</tr>
<tr>
<td><strong>Total Completes</strong></td>
<td>1,028</td>
</tr>
<tr>
<td></td>
<td>324*</td>
</tr>
<tr>
<td></td>
<td>*preliminary</td>
</tr>
</tbody>
</table>
A nationally representative sample of jails was invited to participate in the jail survey.

**3,535**
Jails in sample frame

**2,791**
Jails invited to complete survey

**1,028**
Completed surveys

**36.8%**
Response rate

1. Combined lists from the Bureau of Justice Statistics and National Institute of Corrections, removing duplicates
2. Stratified by U.S. Census region (Northeast, Midwest, South, and West), allocating jails so that each region achieved the same level of precision estimate as possible
3. Weighted final data to be representative of 3,502 jails in final sample frame (after removing invalid/closed facilities and additional duplicates)
# Type of SUD Treatment\(^1\) Available

<table>
<thead>
<tr>
<th>Type of SUD Treatment</th>
<th>Of all jails surveyed</th>
<th>Of jails with any SUD services</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any SUD treatment/recovery services</td>
<td>70.90%</td>
<td></td>
</tr>
<tr>
<td>Self-help meetings (e.g., AA)</td>
<td>43.90%</td>
<td>63.20%</td>
</tr>
<tr>
<td>Services for co-occurring SUD and MH conditions</td>
<td></td>
<td>34.00%</td>
</tr>
<tr>
<td>Therapeutic community</td>
<td>23.40%</td>
<td>33.70%</td>
</tr>
<tr>
<td>Outpatient treatment</td>
<td>23.30%</td>
<td>33.40%</td>
</tr>
<tr>
<td>Other services (not specified)</td>
<td>20.20%</td>
<td>29.00%</td>
</tr>
</tbody>
</table>

1 Survey questions: *Is any kind of substance use treatment or recovery support available to people while they are in this jail? (If yes) Which of the following counseling or recovery support services are available to individuals in this jail?*
Definition of MAT

In this survey, the term “Medications for Addiction Treatment” (MAT) was used intentionally, to:

- Be inclusive of medications that may be in use for alcohol use disorder
- Match the terminology most familiar to survey respondents

In scientific publications using these data, when discussion is limited to the treatment of opioid use disorder, the term MOUD (medications for opioid use disorder) is likely to be used.
Availability of MAT as part of SUD treatment services

- **Any**: 43.00% (as % of all jails surveyed), 62.40% (as % of jails with any SUD services)
- **Buprenorphine**: 30.50% (as % of all jails surveyed), 42.40% (as % of jails with any SUD services)
- **Methadone**: 20.20% (as % of all jails surveyed), 28.10% (as % of jails with any SUD services)
- **Naltrexone**: 23.50% (as % of all jails surveyed), 32.80% (as % of jails with any SUD services)

1 Each question on MAT was asked separately.
### Availability of Each Type of MAT

<table>
<thead>
<tr>
<th>Type</th>
<th>As % of all jails surveyed</th>
<th>As % of jails with any SUD services</th>
<th>As % of jails with any MAT available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buprenorphine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naltrexone</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Each question on MAT was asked separately.
83.2% of jails offering buprenorphine use sublingual form

Among jails who make buprenorphine available, who is it available to?¹

- People who were already on it when booked: 72.60%
- Pregnant women: 41.60%
- Anyone with OUD who requests it: 28.40%
- Induction of individuals pre-release: 23.30%

¹This question was a select all that apply.
Among jails who make methadone available, who is it available to? \(^1\)

- People who were already on it when booked: 79.30%
- Pregnant women: 32.20%
- Anyone with OUD who requests it: 12.40%
- Induction of individuals pre-release: 7.20%

\(^1\)This question was a select all that apply; % do not add to 100%.
71.5% of jails offering naltrexone use injectable form

- Injectable (Vivitrol) 71.50%
- Tablet 16.90%
- Unsure which form 11.60%

Of jails that make it available, who is naltrexone available to?

- People who were already on it when booked 52.60%
- Induction of individuals pre-release 48.40%
- Anyone with OUD who requests it 37.40%

¹This question was a select all that apply; % do not add to 100.
Among jails that offer SUD services, but do not offer MAT, reasons included:

- Lack of adequate, licensed staff: 54.30%
- Policy prohibits use of MAT: 19.40%
- Expense: 16.20%
- Not enough individuals with OUD: 13.70%
- Other reasons (not specified): 26.00%
Watch for additional analyses to be provided soon, including:

- Detailed information on SUD/MAT protocols
- Other SUD treatment services
- Discharge planning services
- Availability and distribution of naloxone
- Regional differences and contextual factors